Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose study of oral MT1980 in healthy volunteers
NL-OMON51342Phase 1Completed
- Sponsor
- Monument Therapeutics
- Start
- May 2022
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in post-operative cognitive decline (POCD) and neuroinflammation comparing MT1980 with Placebo (2 arms). Primary endpoint: Safety and tolerability of MT1980. Started May 2022; status: completed.
02
Drugs
MT1980
03
Conditions
post-operative cognitive decline (POCD)neuroinflammation
Beyond the preview
Go deeper on NL-OMON51342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51342.